Stocks
Allakos Inc.ALLK
NASDAQHealthcareBiotechnology$0.33+0.22%
Focused on developing therapeutics for eosinophil and mast cell-related diseases, this clinical-stage biopharma has faced significant valuation declines after trial setbacks. Investors monitor its lead candidate lirentelimab for gastrointestinal and allergic indications as a potential turnaround play.
Market Cap: $29.7M52W Range: $0.22 – $1.56
Congressional Interest in Allakos Inc. (ALLK)
1 member of Congress has disclosed 1 trade in Allakos Inc. (ALLK), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading ALLK?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-06-16 | Christopher L. Jacobs | buy | $1K – $15K |